[Helicobacter pylori eradication therapy in children]

Area of Science:

• Pediatric Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Proton pump inhibitor-based triple therapies are standard for H. pylori-associated diseases in children globally.
• The Japanese Pediatric Guideline recommends amoxicillin and clarithromycin as first-line H. pylori treatment due to insurance limitations.

Purpose of the Study:

• To address the challenge of high clarithromycin resistance in H. pylori strains in Japan.
• To evaluate the implications of clarithromycin resistance on pediatric H. pylori eradication strategies.

Main Methods:

• Review of current pediatric H. pylori treatment guidelines in Japan.
• Analysis of clarithromycin resistance rates in H. pylori strains.
• Discussion of alternative therapeutic regimens.

Main Results:

• Primary resistance to clarithromycin in Japan affects approximately 30% of H. pylori strains.
• This high resistance rate poses a significant challenge for first-line therapy efficacy.
• Amoxicillin and metronidazole triple therapy is a viable second-line option.

Conclusions:

• The high prevalence of clarithromycin resistance necessitates a re-evaluation of first-line H. pylori treatment in Japanese children.
• Consideration of H. pylori eradication is recommended for children with chronic gastritis, gastric atrophy, or family history of gastric cancer.
• A 'test and treat' strategy is not advised for gastric cancer prevention in pediatric H. pylori cases.